-
Signature
-
/s/ Matthew R. Schob, Attorney-in-Fact
-
Stock symbol
-
OBIO
-
Transactions as of
-
May 8, 2024
-
Transactions value $
-
$0
-
Form type
-
4
-
Date filed
-
5/10/2024, 05:23 PM
Transactions Table
Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
transaction |
OBIO |
Common Stock, par value $0.0001 per share ("Common Stock") |
Award |
$0 |
+22K |
+110% |
$0.00 |
42K |
May 8, 2024 |
Direct |
F1 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
transaction |
OBIO |
Stock Option (Right to Buy) |
Award |
$0 |
+33K |
|
$0.00 |
33K |
May 8, 2024 |
Common Stock |
$33K |
$4.98 |
Direct |
F2 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses:
Remarks:
General Manager and Senior Vice President, Focal Therapies